Maza-Solano, Juan , Palma-Martinez, Carmen , Martin-Jimenez, Daniel , Sanchez-Gomez, Serafin , MORENO LUNA, RAMÓN, Calvo-Henriquez, Christian , Galera-Ruiz, Hugo
No
Acta Otorrinolaringol. Esp.
Article
Científica
1.1
01/05/2024
001241844800001
Aim: Nasal polyposis (CRSwNP) shares type 2 inflammation biomarkers with asthma, allergy or arterial hypertension (AH), including periostin, a predictive marker of severity and post -surgical recurrence of polyposis. Antihypertensives have been shown to decrease periostin expression. We set out to evaluate the effect of antihypertensives on the quality of life of patients with CRSwNP. Materials and methods: Retrospective study of 43 patients with CRSwNP and AH with at least 1 year of follow-up and antihypertensive treatment prescribed after the diagnosis of CRSwNP. Phenotypes were analyzed (F1: isolated CRSwNP; F2: CRSwNP with asthma and/or NERD) and aspects related to quality of life (SNOT -22), clinical severity (VAS), polypoid size (NPS), exacerbations and surgical needs after the initiation of antihypertensive treatment. Results: The predominant phenotype was F1 (62.8%). The number of exacerbations was 19.2% for F1, compared to 31.3% for F2. 34.8% underwent surgery after the start of antihypertensive treatment (F1 = 27.9% and F2 = 6.97%). A significant reduction in polypoid size, SNOT22 (16.4 +/- 19.6 points), and VAS scales ( P < .05) was obtained. Conclusions: Antihypertensives administered in patients with CRSwNP and comorbid AH improve quality of life, reduce polypoid size, and reduce the risk of postoperative recurrence. (c) 2023 Sociedad Espanola de Otorrinolaringolog & imath;a y Cirug & imath;a de Cabeza y Cuello. Published by Elsevier Espa & nacute;a, S.L.U. All rights reserved.
Nasal polyposis; Periostin; Arterial hypertension; SNOT22; Quality of life